Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome

Fertility and Sterility

Volumn 92, Issue 4, 2009, Pages 1372-1377

  Kaya, Cemil ^a   Erkan, Aycan Fahri ^a   Cengiz, S Dinçer ^b   Dünder, Ilkkan ^b   Demirel, Özlem Erbaş ^c   Bilgihan, Ayşe ^c  

^a UFUK UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

AOPP; C reactive protein; carotid ITM; Hcy; MDA; PCOS

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; INSULIN; LIPID; MALONALDEHYDE;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL;

ADULT; BLOOD PROTEINS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; LIPIDS; MALONDIALDEHYDE; OBESITY; OXIDATION-REDUCTION; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; UP-REGULATION; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 70349437372     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.08.016     Document Type: Article

References (36)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
2. Glueck C.J., Papana R., Wang P., Goldenberg N., and Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovary syndrome. Metabolism 52 (2003) 908-915
3. Orio Jr. F., Palomba S., Spinelli L., Cascella T., De Simone B., Di Biase S., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
4. Kelly C., Lyall H., Petrie J.R., Gould G.W., Connell J.M.C., and Dattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 2453-2455
5. Kelly C., Speirs A., Gould G., Petrie J., Lyall H., and Connell J. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
6. Witko-Sarsat V.M., Friedlander C., Capeillère-Blandin T., Nguyen-Khoa A., Nguyen T., Zingraff J., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49 (2002) 1304
7. Liu S.X., Guo Z.J., Nagai R., Zhang W.R., Liu Z.Q., Zhou Z.M., et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stres and inflammation. Arterioscler Thromb Vasc Biol 26 (2006) 1156-1162
8. Boulman N., Levy Y., Leiba R., Schachar S., Linn R., Zinder O., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
9. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
10. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular diesase. N Engl J Med 324 (1995) 1149-1155
11. McCarty M.F. Increased homocysteine associated with smoking, chronic inflammation, and ageing may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypoth 55 (2000) 289-293
12. The Rotterdam ESHRE/ASRM Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
13. Balen A.H., Laven J.S., Tan S.L., and Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9 (2003) 505-514
14. Rebuffe-Scrive M., Cullberg G., Lundberg P.A., Lindstedt G., and Björntorp P. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 21 (1989) 391-397
15. Ashwell M., Chinn S., Stalley S., and Garrow J.S. Female fat distribution-a simple classification based on two circumference measurements. Int J Obes 6 (1982) 143-152
16. Ferriman D., and Gallway J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 (1961) 1440-1447
17. Wofford J., JKahl F., Howard G., McKinney W., Toole J., and Crouse J. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coranary atherosclerosis. Arterioscler Thromb Vasc Biol 11 (1991) 1786-1794
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. diabetes care 21 Suppl 1 (1998) S5-S19
19. Belli S.H., Graffigna M.N., Oneta A., Otero P., Schurman L., and Levalle O.A. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81 (2004) 624-629
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Tracher D.F., and Turner R.I. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1998) 412-419
21. Gutteridge J.M., and Halliwell B. The measurement and mechanism of lipid peroxidation in biological system. Trend Biochem Sci 19 (1989) 129-135
22. Ueland P.M., Refsum H., Beresford S.A.A., and Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72 (2000) 324-332
23. Pasceri V., Willerson J.T., and Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
24. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., Verheugt F.W., Wolbink G.J., and Hack C.E. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 100 (1999) 96-102
25. Drueke T., Witko-Sarsat V., Massy Z., Descamps-Latscha B., Guerin A.P., Marchais S.J., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (2002) 2212-2217
26. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., Nguyen A.T., Gausson V., Mothu N., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 45 (2005) 39-47
27. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., and Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162 (2002) 221-225
28. Sabuncu T., Vural H., Harma M., and Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochemistry 34 (2001) 407
29. Yilmaz M., Bukan N., Ayvaz G., Karakoç A., Törüner F., Çakir N., et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polcystic ovary syndrome. Hum Reprod 20 12 (2005) 3333-3340
30. DiamantiKandarakis E., Papavassiliou A.G., Kandarakis S.A., and Chrousos G.P. Pathophysiology and types of dyslipidemia in PCOS. J Clin Endocrinol Metab 18 (2007) 281-285
31. Guzick D., Talbott E., Sutton-Tyrrell K., Herzog A., Kuller L., and Wolfson S. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case control study. Am J Obstet Gynecol 174 (1996) 1224-1232
32. Talbott E., Guzick D., Sutton-Tyrell K., McHugh-Pemu P., Zborowski J., and Remsberg K. Evidence for the association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
33. Lakhani K., Hardiman P., and Seifalian A. Intima-media thickness of elastic and muscular arteries in young women with polycystic ovaries. Atherosclerosis 175 (2004) 353-359
34. Meyer C., McGrath P., and Teede H.J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90 (2005) 5711-5716
35. Festa A., D'Agostino R.J., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
36. Kalousova M., Skrha J., and Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51 (2002) 597-604